BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//XIMA Media GmbH//xima_typo3_calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:entry-140@www.dkfz.de
DTSTAMP:20260929T155344Z
DTSTART:20260318T100000Z
DTEND:20260318T110000Z
SUMMARY:Cancer Core Europe Lecture: Metabolites as signaling molecules and 
 biomarkers in cancer
DESCRIPTION:Welcome to the next Cancer Core Europe (CCE) Lecture\, hosted b
 y the German Cancer Research Center (DKFZ) and the National Center for Tum
 or Diseases (NCT) Heidelberg. Speaker: Christiane A. Opitz\, Dr. med.\, MS
 c\, Head of the Division of Metabolic Crosstalk in Cancer at the DKFZ Host
 : Stefan Fröhling\, Prof. Dr.\, Managing Director of NCT Heidelberg\, Hea
 d of the Division of Translational Medical Oncology at the DKFZ Date & Tim
 e: Wednesday\, March 18th\, 2026 ‒ Time: 12 - 1 pm CET Zoom link: https:
 //dkfz-de.zoom-x.de/j/64996159988 Abstract Metabolic reprogramming is a ha
 llmark of cancer and leads to the accumulation of metabolites that functio
 n not only as intermediates of cellular metabolism but also as signaling m
 olecules that regulate tumor progression. Increasing evidence demonstrates
  that metabolites can influence transcriptional programs\, cellular signal
 ing pathways\, and immune responses\, thereby linking metabolic states to 
 cancer biology. Among these mechanisms\, metabolites derived from tryptoph
 an metabolism have emerged as critical mediators of tumor-immune interacti
 ons and tumor cell adaptation. Enzymatic degradation of tryptophan generat
 es metabolites capable of activating the aryl hydrocarbon receptor (AHR)\,
  a ligand-activated transcription factor involved in cellular differentiat
 ion\, immune regulation\, and tumor progression. Tryptophan metabolites ac
 t as endogenous AHR agonists and promote transcriptional programs that sup
 port tumor cell survival\, immune suppression\, and adaptation to metaboli
 c stress. Metabolite-mediated signaling is also closely connected to growt
 h-regulatory pathways such as mechanistic target of rapamycin (mTOR)\, whi
 ch integrates nutrient availability and metabolic cues to control cell gro
 wth\, proliferation\, and anabolic metabolism. The interaction between met
 abolic pathways and signaling networks including AHR and mTOR plays a crit
 ical role in the metabolic plasticity of cancer cells and contributes to t
 herapy resistance. Beyond their signaling roles\, tumor-associated metabol
 ites are increasingly explored as clinically relevant biomarkers. Metabolo
 mic profiling enables the identification of metabolic signatures that refl
 ect tumor activity\, immune status\, and therapy response. Interdisciplina
 ry research initiatives such as the BMFTR-funded BALANCE-ET consortium ill
 ustrate this translational approach by investigating systemic metabolic ch
 anges and biomarker signatures associated with relapse risk and long-term 
 outcomes in breast cancer survivors. Such metabolite-based biomarkers may 
 improve risk stratification and long-term monitoring of quality of life in
  cancer survivors. Together\, these findings highlight metabolites as key 
 regulators of oncogenic signaling networks and as promising biomarkers in 
 cancer. What is Cancer Core Europe (CCE)? Cancer Core Europe is a consorti
 um of seven leading cancer centres (www.cancercoreeurope.eu). CCEs members
  are driven by a strong will to reshape the cancer research model to ultim
 ately increase the European Union’s competitiveness as a place to conduc
 t cutting-edge research that’s translated to the clinic to deliver more 
 personalized medicine. Join us for this event and feel free to share it in
  your network!
LOCATION:Online
URL:https://www.dkfz.de/en/news/events/details/193-cancer-core-europe-lectu
 re-metabolites-as-signaling-molecules-and-biomarkers-in-cancer/a140
CATEGORIES:Vorträge und Seminare
STATUS:CONFIRMED
SEQUENCE:1790690401
LAST-MODIFIED:20260929T140001Z
END:VEVENT
END:VCALENDAR